カテゴリー： QYResearch, 世界

世界の骨髄異形成症候群（MDS）治療薬市場 2019年

【英語タイトル】Global Myelodysplastic Syndrome (MDS) Therapeutics Market Professional Survey Report 2019

QYResearchが出版した調査資料（DATA909X11785）・商品コード：DATA909X11785
・発行会社（調査会社）：QYResearch
・発行日：2019年11月20日（※2024年版があります。お問い合わせください）
・ページ数：107
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：機械・装置
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,500 ⇒換算￥518,000見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD5,250 ⇒換算￥777,000見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD7,000 ⇒換算￥1,036,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
※本調査レポートは、骨髄異形成症候群（MDS）治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、アザシチジン、レナリドマイド、デシタビン、デフェラシロクス、その他に、用途別には、入院患者、外来患者にセグメント区分し、骨髄異形成症候群（MDS）治療薬の世界市場を分析しました。


・エグゼクティブ・サマリー
・骨髄異形成症候群（MDS）治療薬の世界市場概要
・骨髄異形成症候群（MDS）治療薬の製造コスト構成分析
・骨髄異形成症候群（MDS）治療薬の開発・製造工場分析
・主要メーカーの主な指標（生産能力、売上、価格分析）
・骨髄異形成症候群（MDS）治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入）
（北米、ヨーロッパ、中国、日本国内、東南アジア、インド）
・骨髄異形成症候群（MDS）治療薬のセグメント分析（種類別）
（アザシチジン、レナリドマイド、デシタビン、デフェラシロクス、その他）
・骨髄異形成症候群（MDS）治療薬のセグメント分析（用途別）
（入院患者、外来患者）
・骨髄異形成症候群（MDS）治療薬の主要メーカー別分析（生産拠点、製品概要、生産・売上実績）
（Novartis AG、Celgene Corporation、Otsuka Pharmaceutical Co., Ltd.、Sandoz Inc.、Dr Reddys Laboratories Limited、Pharmascience Inc.、Accord Healthcare Ltd、Mylan N.V.、）
・骨髄異形成症候群（MDS）治療薬の市場規模予測（2019年～2025年）
（北米、ヨーロッパ、中国、日本国内、東南アジア、インド）
・マーケティングチャネル・流通業者・顧客
・市場ダイナミクス（市場動向、機会、成長要因、課題、影響因子）
...
【レポートの概要】

The global Myelodysplastic Syndrome (MDS) Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
This report focuses on Myelodysplastic Syndrome (MDS) Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Myelodysplastic Syndrome (MDS) Therapeutics market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Myelodysplastic Syndrome (MDS) Therapeutics in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Myelodysplastic Syndrome (MDS) Therapeutics manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Novartis AG
Celgene Corporation
Otsuka Pharmaceutical Co., Ltd.
Sandoz Inc.
Dr Reddys Laboratories Limited
Pharmascience Inc.
Accord Healthcare Ltd
Mylan N.V.

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Azacitidine
Lenalidomide
Decitabine
Deferasirox
Others

Segment by Application
In-Patient
Out-Patient

【レポートの目次】

Table of Contents

Executive Summary
1 Industry Overview of Myelodysplastic Syndrome (MDS) Therapeutics
1.1 Definition of Myelodysplastic Syndrome (MDS) Therapeutics
1.2 Myelodysplastic Syndrome (MDS) Therapeutics Segment by Type
1.2.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Production Growth Rate Comparison by Types (2014-2025)
1.2.2 Azacitidine
1.2.3 Lenalidomide
1.2.4 Decitabine
1.2.5 Deferasirox
1.2.6 Others
1.3 Myelodysplastic Syndrome (MDS) Therapeutics Segment by Applications
1.3.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Consumption Comparison by Applications (2014-2025)
1.3.2 In-Patient
1.3.3 Out-Patient
1.4 Global Myelodysplastic Syndrome (MDS) Therapeutics Overall Market
1.4.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue (2014-2025)
1.4.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Production (2014-2025)
1.4.3 North America Myelodysplastic Syndrome (MDS) Therapeutics Status and Prospect (2014-2025)
1.4.4 Europe Myelodysplastic Syndrome (MDS) Therapeutics Status and Prospect (2014-2025)
1.4.5 China Myelodysplastic Syndrome (MDS) Therapeutics Status and Prospect (2014-2025)
1.4.6 Japan Myelodysplastic Syndrome (MDS) Therapeutics Status and Prospect (2014-2025)
1.4.7 Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Status and Prospect (2014-2025)
1.4.8 India Myelodysplastic Syndrome (MDS) Therapeutics Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Myelodysplastic Syndrome (MDS) Therapeutics
2.3 Manufacturing Process Analysis of Myelodysplastic Syndrome (MDS) Therapeutics
2.4 Industry Chain Structure of Myelodysplastic Syndrome (MDS) Therapeutics

3 Development and Manufacturing Plants Analysis of Myelodysplastic Syndrome (MDS) Therapeutics
3.1 Capacity and Commercial Production Date
3.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Manufacturing Plants Distribution
3.3 Major Manufacturers Technology Source and Market Position of Myelodysplastic Syndrome (MDS) Therapeutics
3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers
4.1 Myelodysplastic Syndrome (MDS) Therapeutics Production and Capacity Analysis
4.2 Myelodysplastic Syndrome (MDS) Therapeutics Revenue Analysis
4.3 Myelodysplastic Syndrome (MDS) Therapeutics Price Analysis
4.4 Market Concentration Degree

5 Myelodysplastic Syndrome (MDS) Therapeutics Regional Market Analysis
5.1 Myelodysplastic Syndrome (MDS) Therapeutics Production by Regions
5.1.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Production by Regions
5.1.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue by Regions
5.2 Myelodysplastic Syndrome (MDS) Therapeutics Consumption by Regions
5.3 North America Myelodysplastic Syndrome (MDS) Therapeutics Market Analysis
5.3.1 North America Myelodysplastic Syndrome (MDS) Therapeutics Production
5.3.2 North America Myelodysplastic Syndrome (MDS) Therapeutics Revenue
5.3.3 Key Manufacturers in North America
5.3.4 North America Myelodysplastic Syndrome (MDS) Therapeutics Import and Export
5.4 Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Analysis
5.4.1 Europe Myelodysplastic Syndrome (MDS) Therapeutics Production
5.4.2 Europe Myelodysplastic Syndrome (MDS) Therapeutics Revenue
5.4.3 Key Manufacturers in Europe
5.4.4 Europe Myelodysplastic Syndrome (MDS) Therapeutics Import and Export
5.5 China Myelodysplastic Syndrome (MDS) Therapeutics Market Analysis
5.5.1 China Myelodysplastic Syndrome (MDS) Therapeutics Production
5.5.2 China Myelodysplastic Syndrome (MDS) Therapeutics Revenue
5.5.3 Key Manufacturers in China
5.5.4 China Myelodysplastic Syndrome (MDS) Therapeutics Import and Export
5.6 Japan Myelodysplastic Syndrome (MDS) Therapeutics Market Analysis
5.6.1 Japan Myelodysplastic Syndrome (MDS) Therapeutics Production
5.6.2 Japan Myelodysplastic Syndrome (MDS) Therapeutics Revenue
5.6.3 Key Manufacturers in Japan
5.6.4 Japan Myelodysplastic Syndrome (MDS) Therapeutics Import and Export
5.7 Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Market Analysis
5.7.1 Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Production
5.7.2 Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Revenue
5.7.3 Key Manufacturers in Southeast Asia
5.7.4 Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Import and Export
5.8 India Myelodysplastic Syndrome (MDS) Therapeutics Market Analysis
5.8.1 India Myelodysplastic Syndrome (MDS) Therapeutics Production
5.8.2 India Myelodysplastic Syndrome (MDS) Therapeutics Revenue
5.8.3 Key Manufacturers in India
5.8.4 India Myelodysplastic Syndrome (MDS) Therapeutics Import and Export

6 Myelodysplastic Syndrome (MDS) Therapeutics Segment Market Analysis (by Type)
6.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Production by Type
6.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue by Type
6.3 Myelodysplastic Syndrome (MDS) Therapeutics Price by Type

7 Myelodysplastic Syndrome (MDS) Therapeutics Segment Market Analysis (by Application)
7.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Consumption by Application
7.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Consumption Market Share by Application (2014-2019)

8 Myelodysplastic Syndrome (MDS) Therapeutics Major Manufacturers Analysis
8.1 Novartis AG
8.1.1 Novartis AG Myelodysplastic Syndrome (MDS) Therapeutics Production Sites and Area Served
8.1.2 Novartis AG Product Introduction, Application and Specification
8.1.3 Novartis AG Myelodysplastic Syndrome (MDS) Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.1.4 Main Business and Markets Served
8.2 Celgene Corporation
8.2.1 Celgene Corporation Myelodysplastic Syndrome (MDS) Therapeutics Production Sites and Area Served
8.2.2 Celgene Corporation Product Introduction, Application and Specification
8.2.3 Celgene Corporation Myelodysplastic Syndrome (MDS) Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.2.4 Main Business and Markets Served
8.3 Otsuka Pharmaceutical Co., Ltd.
8.3.1 Otsuka Pharmaceutical Co., Ltd. Myelodysplastic Syndrome (MDS) Therapeutics Production Sites and Area Served
8.3.2 Otsuka Pharmaceutical Co., Ltd. Product Introduction, Application and Specification
8.3.3 Otsuka Pharmaceutical Co., Ltd. Myelodysplastic Syndrome (MDS) Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.3.4 Main Business and Markets Served
8.4 Sandoz Inc.
8.4.1 Sandoz Inc. Myelodysplastic Syndrome (MDS) Therapeutics Production Sites and Area Served
8.4.2 Sandoz Inc. Product Introduction, Application and Specification
8.4.3 Sandoz Inc. Myelodysplastic Syndrome (MDS) Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.4.4 Main Business and Markets Served
8.5 Dr Reddys Laboratories Limited
8.5.1 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Therapeutics Production Sites and Area Served
8.5.2 Dr Reddys Laboratories Limited Product Introduction, Application and Specification
8.5.3 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.5.4 Main Business and Markets Served
8.6 Pharmascience Inc.
8.6.1 Pharmascience Inc. Myelodysplastic Syndrome (MDS) Therapeutics Production Sites and Area Served
8.6.2 Pharmascience Inc. Product Introduction, Application and Specification
8.6.3 Pharmascience Inc. Myelodysplastic Syndrome (MDS) Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.6.4 Main Business and Markets Served
8.7 Accord Healthcare Ltd
8.7.1 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Therapeutics Production Sites and Area Served
8.7.2 Accord Healthcare Ltd Product Introduction, Application and Specification
8.7.3 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.7.4 Main Business and Markets Served
8.8 Mylan N.V.
8.8.1 Mylan N.V. Myelodysplastic Syndrome (MDS) Therapeutics Production Sites and Area Served
8.8.2 Mylan N.V. Product Introduction, Application and Specification
8.8.3 Mylan N.V. Myelodysplastic Syndrome (MDS) Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.8.4 Main Business and Markets Served

9 Development Trend of Analysis of Myelodysplastic Syndrome (MDS) Therapeutics Market
9.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Trend Analysis
9.1.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size (Volume and Value) Forecast 2019-2025
9.2 Myelodysplastic Syndrome (MDS) Therapeutics Regional Market Trend
9.2.1 North America Myelodysplastic Syndrome (MDS) Therapeutics Forecast 2019-2025
9.2.2 Europe Myelodysplastic Syndrome (MDS) Therapeutics Forecast 2019-2025
9.2.3 China Myelodysplastic Syndrome (MDS) Therapeutics Forecast 2019-2025
9.2.4 Japan Myelodysplastic Syndrome (MDS) Therapeutics Forecast 2019-2025
9.2.5 Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Forecast 2019-2025
9.2.6 India Myelodysplastic Syndrome (MDS) Therapeutics Forecast 2019-2025
9.3 Myelodysplastic Syndrome (MDS) Therapeutics Market Trend (Product Type)
9.4 Myelodysplastic Syndrome (MDS) Therapeutics Market Trend (Application)

10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.3 Myelodysplastic Syndrome (MDS) Therapeutics Customers

11 Market Dynamics
11.1 Market Trends
11.2 Opportunities
11.3 Market Drivers
11.4 Challenges
11.5 Influence Factors

12 Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer

List of Tables and Figures
Figure Picture of Myelodysplastic Syndrome (MDS) Therapeutics
Table Global Myelodysplastic Syndrome (MDS) Therapeutics Production (K Pcs) Growth Rate Comparison by Types (2014-2025)
Figure Global Myelodysplastic Syndrome (MDS) Therapeutics Production Market Share by Types in 2018
Figure Azacitidine Product Picture
Figure Lenalidomide Product Picture
Figure Decitabine Product Picture
Figure Deferasirox Product Picture
Figure Others Product Picture
Table Global Myelodysplastic Syndrome (MDS) Therapeutics Consumption (K Pcs) Comparison by Applications (2014-2025)
Figure Global Myelodysplastic Syndrome (MDS) Therapeutics Consumption Market Share by Applications in 2018
Figure In-Patient
Figure Out-Patient
Figure Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue (Million USD) (2014-2025)
Figure Global Myelodysplastic Syndrome (MDS) Therapeutics Production (K Pcs) (2014-2025)
Figure North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size (Million USD) (2014-2025)
Figure Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size (Million USD) (2014-2025)
Figure China Myelodysplastic Syndrome (MDS) Therapeutics Market Size (Million USD) (2014-2025)
Figure Japan Myelodysplastic Syndrome (MDS) Therapeutics Market Size (Million USD) (2014-2025)
Figure Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Market Size (Million USD) (2014-2025)
Figure India Myelodysplastic Syndrome (MDS) Therapeutics Market Size (Million USD) (2014-2025)
Table Myelodysplastic Syndrome (MDS) Therapeutics Raw Material and Suppliers
Table Manufacturing Cost Structure Analysis of Myelodysplastic Syndrome (MDS) Therapeutics in 2018
Figure Manufacturing Process Analysis of Myelodysplastic Syndrome (MDS) Therapeutics
Figure Industry Chain Structure of Myelodysplastic Syndrome (MDS) Therapeutics
Table Capacity and Commercial Production Date of Key Manufacturers
Table Global Myelodysplastic Syndrome (MDS) Therapeutics Manufacturing Plants Distribution
Table Myelodysplastic Syndrome (MDS) Therapeutics Major Manufacturers Technology Source and Market Position
Table Recent Development and Expansion Plans in Future
Table Myelodysplastic Syndrome (MDS) Therapeutics Capacity (K Pcs) of Major Manufacturers (2014-2019)
Table Myelodysplastic Syndrome (MDS) Therapeutics Production (K Pcs) of Major Manufacturers (2014-2019)
Table Myelodysplastic Syndrome (MDS) Therapeutics Production Market Share of Major Manufacturers (2014-2019)
Figure Myelodysplastic Syndrome (MDS) Therapeutics Production Share by Manufacturers in 2018
Table Myelodysplastic Syndrome (MDS) Therapeutics Revenue (Million US$) of Major Manufacturers (2014-2019)
Table Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share of Major Manufacturers (2014-2019)
Figure Myelodysplastic Syndrome (MDS) Therapeutics Revenue Share by Manufacturers in 2018
Table Myelodysplastic Syndrome (MDS) Therapeutics Average Price (USD/Pcs) of Major Manufacturers (2014-2019)
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Global Myelodysplastic Syndrome (MDS) Therapeutics Production by Regions 2014-2019 (K Pcs)
Table Global Myelodysplastic Syndrome (MDS) Therapeutics Production Market Share by Regions 2014-2019
Figure Global Myelodysplastic Syndrome (MDS) Therapeutics Production Market Share by Regions in 2018
Table Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue by Regions 2014-2019 (Million USD)
Table Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share by Regions 2014-2019
Figure Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share by Regions in 2018
Table Global Myelodysplastic Syndrome (MDS) Therapeutics Consumption by Regions 2014-2019 (K Pcs)
Table Global Myelodysplastic Syndrome (MDS) Therapeutics Consumption Market Share by Regions 2014-2019
Figure North America Myelodysplastic Syndrome (MDS) Therapeutics Production Growth Rate 2014-2019 (K Pcs)
Figure North America Myelodysplastic Syndrome (MDS) Therapeutics Revenue Growth Rate 2014-2019 (Million USD)
Table North America Myelodysplastic Syndrome (MDS) Therapeutics Production, Consumption Import and Export (K Pcs)
Figure Europe Myelodysplastic Syndrome (MDS) Therapeutics Production Growth Rate 2014-2019 (K Pcs)
Figure Europe Myelodysplastic Syndrome (MDS) Therapeutics Revenue Growth Rate 2014-2019 (Million USD)
Table Europe Myelodysplastic Syndrome (MDS) Therapeutics Production, Consumption Import and Export (K Pcs)
Figure China Myelodysplastic Syndrome (MDS) Therapeutics Production Growth Rate 2014-2019 (K Pcs)
Figure China Myelodysplastic Syndrome (MDS) Therapeutics Revenue Growth Rate 2014-2019 (Million USD)
Table China Myelodysplastic Syndrome (MDS) Therapeutics Production, Consumption Import and Export (K Pcs)
Figure Japan Myelodysplastic Syndrome (MDS) Therapeutics Production Growth Rate 2014-2019 (K Pcs)
Figure Japan Myelodysplastic Syndrome (MDS) Therapeutics Revenue Growth Rate 2014-2019 (Million USD)
Table Japan Myelodysplastic Syndrome (MDS) Therapeutics Production, Consumption Import and Export (K Pcs)
Figure Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Production Growth Rate 2014-2019 (K Pcs)
Figure Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Revenue Growth Rate 2014-2019 (Million USD)
Table Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Production, Consumption Import and Export (K Pcs)
Figure India Myelodysplastic Syndrome (MDS) Therapeutics Production Growth Rate 2014-2019 (K Pcs)
Figure India Myelodysplastic Syndrome (MDS) Therapeutics Revenue Growth Rate 2014-2019 (Million USD)
Table India Myelodysplastic Syndrome (MDS) Therapeutics Production, Consumption Import and Export (K Pcs)
Figure Global Consumption Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Application (2014-2019)
Figure Global Value (Consumption) Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Application (2014-2019)
Table Novartis AG Myelodysplastic Syndrome (MDS) Therapeutics Production Sites and Area Served
Table Novartis AG Myelodysplastic Syndrome (MDS) Therapeutics Product Introduction, Application and Specification
Table Novartis AG Myelodysplastic Syndrome (MDS) Therapeutics Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Novartis AG Myelodysplastic Syndrome (MDS) Therapeutics Production Growth Rate (2014-2019)
Table Novartis AG Myelodysplastic Syndrome (MDS) Therapeutics Production Market Share (2014-2019)
Figure Novartis AG Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share (2014-2019)
Table Novartis AG Myelodysplastic Syndrome (MDS) Therapeutics Main Business and Markets Served
Table Celgene Corporation Myelodysplastic Syndrome (MDS) Therapeutics Production Sites and Area Served
Table Celgene Corporation Myelodysplastic Syndrome (MDS) Therapeutics Product Introduction, Application and Specification
Table Celgene Corporation Myelodysplastic Syndrome (MDS) Therapeutics Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Celgene Corporation Myelodysplastic Syndrome (MDS) Therapeutics Production Growth Rate (2014-2019)
Table Celgene Corporation Myelodysplastic Syndrome (MDS) Therapeutics Production Market Share (2014-2019)
Figure Celgene Corporation Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share (2014-2019)
Table Celgene Corporation Myelodysplastic Syndrome (MDS) Therapeutics Main Business and Markets Served
Table Otsuka Pharmaceutical Co., Ltd. Myelodysplastic Syndrome (MDS) Therapeutics Production Sites and Area Served
Table Otsuka Pharmaceutical Co., Ltd. Myelodysplastic Syndrome (MDS) Therapeutics Product Introduction, Application and Specification
Table Otsuka Pharmaceutical Co., Ltd. Myelodysplastic Syndrome (MDS) Therapeutics Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Otsuka Pharmaceutical Co., Ltd. Myelodysplastic Syndrome (MDS) Therapeutics Production Growth Rate (2014-2019)
Table Otsuka Pharmaceutical Co., Ltd. Myelodysplastic Syndrome (MDS) Therapeutics Production Market Share (2014-2019)
Figure Otsuka Pharmaceutical Co., Ltd. Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share (2014-2019)
Table Otsuka Pharmaceutical Co., Ltd. Myelodysplastic Syndrome (MDS) Therapeutics Main Business and Markets Served
Table Sandoz Inc. Myelodysplastic Syndrome (MDS) Therapeutics Production Sites and Area Served
Table Sandoz Inc. Myelodysplastic Syndrome (MDS) Therapeutics Product Introduction, Application and Specification
Table Sandoz Inc. Myelodysplastic Syndrome (MDS) Therapeutics Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Sandoz Inc. Myelodysplastic Syndrome (MDS) Therapeutics Production Growth Rate (2014-2019)
Table Sandoz Inc. Myelodysplastic Syndrome (MDS) Therapeutics Production Market Share (2014-2019)
Figure Sandoz Inc. Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share (2014-2019)
Table Sandoz Inc. Myelodysplastic Syndrome (MDS) Therapeutics Main Business and Markets Served
Table Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Therapeutics Production Sites and Area Served
Table Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Therapeutics Product Introduction, Application and Specification
Table Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Therapeutics Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Therapeutics Production Growth Rate (2014-2019)
Table Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Therapeutics Production Market Share (2014-2019)
Figure Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share (2014-2019)
Table Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Therapeutics Main Business and Markets Served
Table Pharmascience Inc. Myelodysplastic Syndrome (MDS) Therapeutics Production Sites and Area Served
Table Pharmascience Inc. Myelodysplastic Syndrome (MDS) Therapeutics Product Introduction, Application and Specification
Table Pharmascience Inc. Myelodysplastic Syndrome (MDS) Therapeutics Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Pharmascience Inc. Myelodysplastic Syndrome (MDS) Therapeutics Production Growth Rate (2014-2019)
Table Pharmascience Inc. Myelodysplastic Syndrome (MDS) Therapeutics Production Market Share (2014-2019)
Figure Pharmascience Inc. Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share (2014-2019)
Table Pharmascience Inc. Myelodysplastic Syndrome (MDS) Therapeutics Main Business and Markets Served
Table Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Therapeutics Production Sites and Area Served
Table Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Therapeutics Product Introduction, Application and Specification
Table Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Therapeutics Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Therapeutics Production Growth Rate (2014-2019)
Table Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Therapeutics Production Market Share (2014-2019)
Figure Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share (2014-2019)
Table Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Therapeutics Main Business and Markets Served
Table Mylan N.V. Myelodysplastic Syndrome (MDS) Therapeutics Production Sites and Area Served
Table Mylan N.V. Myelodysplastic Syndrome (MDS) Therapeutics Product Introduction, Application and Specification
Table Mylan N.V. Myelodysplastic Syndrome (MDS) Therapeutics Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Mylan N.V. Myelodysplastic Syndrome (MDS) Therapeutics Production Growth Rate (2014-2019)
Table Mylan N.V. Myelodysplastic Syndrome (MDS) Therapeutics Production Market Share (2014-2019)
Figure Mylan N.V. Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share (2014-2019)
Table Mylan N.V. Myelodysplastic Syndrome (MDS) Therapeutics Main Business and Markets Served
Figure Global Myelodysplastic Syndrome (MDS) Therapeutics Production (K Pcs) Growth Rate Forecast 2019-2025
Figure Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue (Million USD) Growth Rate Forecast 2019-2025
Figure Global Myelodysplastic Syndrome (MDS) Therapeutics Sales Price (USD/Pcs) Forecast 2019-2025
Figure North America Myelodysplastic Syndrome (MDS) Therapeutics Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure North America Myelodysplastic Syndrome (MDS) Therapeutics Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Europe Myelodysplastic Syndrome (MDS) Therapeutics Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Europe Myelodysplastic Syndrome (MDS) Therapeutics Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure China Myelodysplastic Syndrome (MDS) Therapeutics Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure China Myelodysplastic Syndrome (MDS) Therapeutics Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Japan Myelodysplastic Syndrome (MDS) Therapeutics Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Japan Myelodysplastic Syndrome (MDS) Therapeutics Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure India Myelodysplastic Syndrome (MDS) Therapeutics Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure India Myelodysplastic Syndrome (MDS) Therapeutics Revenue Growth Rate Forecast 2019-2025 (Million USD)
Table Global Production (K Pcs) of Myelodysplastic Syndrome (MDS) Therapeutics by Type (2019-2025)
Table Global Consumption (K Pcs) of Myelodysplastic Syndrome (MDS) Therapeutics by Application (2019-2025)
Table Myelodysplastic Syndrome (MDS) Therapeutics Distributors List
Table Myelodysplastic Syndrome (MDS) Therapeutics Customers List
Table Market Key Trends
Table Key Opportunities
Table Market Key Drivers
Table Key Challenges
Table Key Influence Factors
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources


【掲載企業】

Novartis AG、Celgene Corporation、Otsuka Pharmaceutical Co., Ltd.、Sandoz Inc.、Dr Reddys Laboratories Limited、Pharmascience Inc.、Accord Healthcare Ltd、Mylan N.V.、

★調査レポート[世界の骨髄異形成症候群（MDS）治療薬市場 2019年] (コード：DATA909X11785)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の骨髄異形成症候群（MDS）治療薬市場 2019年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の急性呼吸窮迫症候群(ARDS)治療薬市場 2019年
    DATA909X02949 / QYResearch / 2019年11月15日 / ※本調査レポートは、急性呼吸窮迫症候群(ARDS)治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、メチルプレドニゾロン、ヒドロコルチゾン、注射用子牛肺サーファクタント、その他に、用途別には、入院患者、外来患者にセグメント区分し、急性呼吸窮迫症候群(ARDS)治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・急性呼吸窮迫症候群(ARDS)治療薬の世界市場概要 ・急性呼吸窮迫症候群(ARDS)治療薬の製造コスト構成分析 ・急性呼吸窮迫症候群(ARDS)治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・急性呼吸窮迫症候群(ARDS)治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・急性呼吸窮迫症候群(ARDS)治療薬のセグメント分析（種類別） （メチルプレドニゾロン、ヒドロコルチゾン、注射用子牛肺サーファクタント、その他）...The global Acute Respiratory Distress Syndrome Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Acute Respiratory Distress Syndrome Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Acute Respiratory Distress Syndrome Therapeutics market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Acute Respiratory Distress Syndrome Therapeutics in North America, Europe, China, Japan, Southeast Asia and...
  • 世界の多嚢胞性卵巣症候群（PCOS）治療薬市場 2019年
    DATA909X13285 / QYResearch / 2019年11月20日 / ※本調査レポートは、多嚢胞性卵巣症候群（PCOS）治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、経口避妊薬、抗炎症薬、インスリン抵抗性改善薬、抗高血圧薬、抗肥満薬に、用途別には、病院、クリニックにセグメント区分し、多嚢胞性卵巣症候群（PCOS）治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・多嚢胞性卵巣症候群（PCOS）治療薬の世界市場概要 ・多嚢胞性卵巣症候群（PCOS）治療薬の製造コスト構成分析 ・多嚢胞性卵巣症候群（PCOS）治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・多嚢胞性卵巣症候群（PCOS）治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・多嚢胞性卵巣症候群（PCOS）治療薬のセグメント分析（種類別） （経口避妊薬、抗炎症薬、インスリン抵抗性改善薬、抗高血圧薬、抗肥満薬）...The global Polycystic Ovary Syndrome (PCOS) Drugs market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Polycystic Ovary Syndrome (PCOS) Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Polycystic Ovary Syndrome (PCOS) Drugs market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Polycystic Ovary Syndrome (PCOS) Drugs in North America, Europe, China, Japan, Southeast Asia and...
  • 世界の急性心不全(AHF)治療薬市場 2019年
    DATA909X02947 / QYResearch / 2019年11月15日 / ※本調査レポートは、急性心不全(AHF)治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、β遮断薬、カルシウム拮抗薬、強心配糖体、利尿薬、モルヒネ、血管拡張薬/硝酸塩、その他に、用途別には、病院、クリニック、ホームケアにセグメント区分し、急性心不全(AHF)治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・急性心不全(AHF)治療薬の世界市場概要 ・急性心不全(AHF)治療薬の製造コスト構成分析 ・急性心不全(AHF)治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・急性心不全(AHF)治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・急性心不全(AHF)治療薬のセグメント分析（種類別） （β遮断薬、カルシウム拮抗薬、強心配糖体、利尿薬、モルヒネ、血管拡張薬/硝酸塩、その他）...The global Acute Heart Failure (AHF) Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Acute Heart Failure (AHF) Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Acute Heart Failure (AHF) Therapeutics market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Acute Heart Failure (AHF) Therapeutics in North America, Europe, China, Japan, Southeast Asia and...
  • 世界の呼吸器合胞体ウイルス（RSV）治療薬市場 2019年
    DATA909X14332 / QYResearch / 2019年11月20日 / ※本調査レポートは、呼吸器合胞体ウイルス（RSV）治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、パリビズマブ、リバビリン、その他に、用途別には、病院薬局、ドラッグストア、小売薬局、その他にセグメント区分し、呼吸器合胞体ウイルス（RSV）治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・呼吸器合胞体ウイルス（RSV）治療薬の世界市場概要 ・呼吸器合胞体ウイルス（RSV）治療薬の製造コスト構成分析 ・呼吸器合胞体ウイルス（RSV）治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・呼吸器合胞体ウイルス（RSV）治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・呼吸器合胞体ウイルス（RSV）治療薬のセグメント分析（種類別） （パリビズマブ、リバビリン、その他）...The global Respiratory Syncytial Virus (RSV) Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Respiratory Syncytial Virus (RSV) Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Respiratory Syncytial Virus (RSV) Therapeutics market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Respiratory Syncytial Virus (RSV) Therapeutics in North America, Europe, China, Japan, Southeast Asia and...
  • 世界の多発性硬化症（MS）治療薬市場 2019年
    DATA909X11757 / QYResearch / 2019年11月20日 / ※本調査レポートは、多発性硬化症（MS）治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、コパキソン（酢酸グラチラマー、共重合体1）、ノバントロン（ミトキサントロン）、ギレニア（フィンゴリモド、Fty720）、オーバジオ（テリフルノミド）、テクフィデラ（フマル酸ジメチル）、フィラテグラス（Sb683699、T-0047）、シポニモド（Baf312）、その他に、用途別には、RRMS、SPMS、PPMS、PRMSにセグメント区分し、多発性硬化症（MS）治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・多発性硬化症（MS）治療薬の世界市場概要 ・多発性硬化症（MS）治療薬の製造コスト構成分析 ・多発性硬化症（MS）治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・多発性硬化症（MS）治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・多発性硬化症（MS）治療薬のセグメント分析（種類別） （コパキソン（酢酸グラチラマー、共重合体1）、ノバントロン（ミトキサントロン）、ギレニア（フィンゴリモド、Fty720）、オーバジオ（テリフルノミド）、テクフィデラ（フマル酸ジメチル）、フィラテグラス（Sb683699、T-0047）、シポニモド（Baf312）、その他）...The global Multiple Sclerosis (MS) Drugs market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Multiple Sclerosis (MS) Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Multiple Sclerosis (MS) Drugs market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Multiple Sclerosis (MS) Drugs in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer...
  • 世界の肺動脈高血圧症（PAH）治療薬市場 2019年
    DATA909X13888 / QYResearch / 2019年11月20日 / ※本調査レポートは、肺動脈高血圧症（PAH）治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、エンドセリン受容体拮抗薬（ERA）、プロスタサイクリンおよびプロスタサイクリンアナログ、ホスホジエステラーゼ5（PDE-5）、可溶性グアニル酸シクラーゼ（SGC）刺激剤に、用途別には、二次性肺高血圧症（SPH）、原発性肺高血圧症（PPH）にセグメント区分し、肺動脈高血圧症（PAH）治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・肺動脈高血圧症（PAH）治療薬の世界市場概要 ・肺動脈高血圧症（PAH）治療薬の製造コスト構成分析 ・肺動脈高血圧症（PAH）治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・肺動脈高血圧症（PAH）治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・肺動脈高血圧症（PAH）治療薬のセグメント分析（種類別） （エンドセリン受容体拮抗薬（ERA）、プロスタサイクリンおよびプロスタサイクリンアナログ、ホスホジエステラーゼ5（PDE-5）、可溶性グアニル酸シクラーゼ（SGC）刺激剤）...The global Pulmonary Arterial Hypertension (PAH) Medicine market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Pulmonary Arterial Hypertension (PAH) Medicine volume and value at global level, regional level and company level. From a global perspective, this report represents overall Pulmonary Arterial Hypertension (PAH) Medicine market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Pulmonary Arterial Hypertension (PAH) Medicine in North America, Europe, China, Japan, Southeast Asia and...
  • 世界のレット症候群治療薬市場 2019年
    DATA909X14357 / QYResearch / 2019年11月20日 / ※本調査レポートは、レット症候群治療薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、BHV-5000、ブリオスタチン-1、CPT-157633、ELX-02、その他に、用途別には、病院、診療所、その他にセグメント区分し、レット症候群治療薬の世界市場を分析しました。 ・エグゼクティブ・サマリー ・レット症候群治療薬の世界市場概要 ・レット症候群治療薬の製造コスト構成分析 ・レット症候群治療薬の開発・製造工場分析 ・主要メーカーの主な指標（生産能力、売上、価格分析） ・レット症候群治療薬の地域別分析（生産、売上、主要メーカー、輸出・輸入） （北米、ヨーロッパ、中国、日本国内、東南アジア、インド） ・レット症候群治療薬のセグメント分析（種類別） （BHV-5000、ブリオスタチン-1、CPT-157633、ELX-02、その他）...The global Rett Syndrome Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Rett Syndrome Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Rett Syndrome Therapeutics market size by analyzing historical data and future prospect. Regionally, this report categorizes the production, apparent consumption, export and import of Rett Syndrome Therapeutics in North America, Europe, China, Japan, Southeast Asia and India. For each manufacturer covered, this report analyzes...
  • 多嚢胞性卵巣症候群（PCOS）治療法の世界市場：規模・現状・予測2019-2025
    DATA909X18843 / QYResearch / 2019年11月25日 / ※当調査レポートでは、多嚢胞性卵巣症候群（PCOS）治療法の世界市場について調査・分析し、多嚢胞性卵巣症候群（PCOS）治療法の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（経口避妊薬、排卵誘発剤、顔面発毛抑制剤、インスリン感作剤）、用途別（病院、診療所、その他）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界の多嚢胞性卵巣症候群（PCOS）治療法市場動向 ・主要企業別マーケットシェア ・多嚢胞性卵巣症候群（PCOS）治療法の種類別市場規模2014-2019 （経口避妊薬、排卵誘発剤、顔面発毛抑制剤、インスリン感作剤） ・多嚢胞性卵巣症候群（PCOS）治療法の用途別市場規模2014-2019 （病院、診療所、その他） ・多嚢胞性卵巣症候群（PCOS）治療法の北米市場：主要企業・種類別/用途別市場規模 ・多嚢胞性卵巣症候群（PCOS）治療法のヨーロッパ市場：主要企業・種類別/用途別市場規模...Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age. In 2018, the global Polycystic Ovarian Syndrome (PCOS) Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Polycystic Ovarian Syndrome (PCOS) Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Polycystic Ovarian Syndrome (PCOS) Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America....

    • ◆H&Iグローバルリサーチのお客様（例）◆